pharma Β· Chronic Spontaneous Urticaria Β· Asthma
Novartis India
Novartis Pharmaceuticals
Novartis India trial registry β 348 ClinicalTrials.gov studies with program phase, status, and indication context.
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
Novartis India clinical trials
Registry index of 348 ClinicalTrials.gov studies linked to Novartis India programs β each row shows trial ID, program name, phase, status, and indication.
Novartis India trial registry β 348 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Novartis India.
-
CAIN457H1301 β Phase 3
Clinical update -
CVAY736B2201 β Phase 3
Clinical update -
CTNO155X2101 β Phase 1
Clinical update -
CIDH305X2101 β Phase 1
Clinical update -
CIAG933A12101 β Phase 1
Clinical update -
CFTY720D2311 β Phase 3
Clinical update -
CCFZ533H12201BC β Phase 2
Clinical update -
CVHB937A12201 β Phase 2
Clinical update
Trial registry
-
CTIS β -
CTIS β -
CTIS β - 2022-502381-25-01CTIS β
CKFA115A12101
Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-503925-20-00CTIS β
CAAA617A12202
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.
-
CTIS β - 2023-504350-36-00CTIS β
Phase I study of MGY825 in patients with lung cancer
Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
- 2023-504419-34-00CTIS β
CMAS825D12201
Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.
-
CTIS β -
CTIS β - 2023-505283-11-00CTIS β
Kesimpta 20 mg solution for injection in pre-filled syringe
Relapsing forms of Multiple Sclerosis (RMS)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-506716-41-00CTIS β
CJDQ443E12101
Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
-
CTIS β -
CTIS β -
CTIS β - 2023-507062-34-00CTIS β
CYTB323A12101
High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia
-
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-507430-25-00CTIS β
Study of PIT565 in relapsed and/or refractory B-cell malignancies
Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
-
CTIS β -
CTIS β -
CTIS β - 2023-507557-16-00CTIS β
CABL001A2001B
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
-
CTIS β -
CTIS β - 2023-507672-52-00CTIS β
CAAA802A12101
PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.
- 2023-507674-41-00CTIS β
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers
Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-508002-20-00CTIS β
CDZR123A02101
advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))
-
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-508128-37-00CTIS β
CCTL019A2205B
All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication
- 2023-508129-28-00CTIS β
CABL001I12201
Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
-
CTIS β -
CTIS β - 2023-508343-48-00CTIS β
CCTL019H2301
Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
- 2023-508369-34-00CTIS β
CIAG933A12101
Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-508950-24-00CTIS β
CPI-0610, CPI-0610
Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)
-
CTIS β -
CTIS β - 2023-508995-12-01CTIS β
CAAA614A12101
Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)
- 2023-508996-35-00CTIS β
CVAY736A2202
Rheumatoid Arthritis, SjΓΆgrenβs Disease, Systemic Lupus erythematosus
-
CTIS β - 2023-509167-24-00CTIS β
CBYL719X2402
Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-509343-27-00CTIS β
IPTACOPAN HYDROCHLORIDE, IPTACOPAN
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis
-
CTIS β -
CTIS β - 2023-509451-14-00CTIS β
DYP688
Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2023-510082-10-00CTIS β
CJDQ443B12301
Advanced non-small cell lung cancer harboring the KRAS G12C mutation
- 2023-510150-17-00CTIS β
CYTB323J12201
Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)
- 2023-510356-23-00CTIS β
CFXX489A12101
Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)
- 2023-510357-42-00CTIS β
CLEE011O12301C
hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).
-
CTIS β -
CTIS β - 2023-510525-15-00CTIS β
CLNP023R12201
active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis
-
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2024-510782-42-00CTIS β
CBYL719K12301
Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
-
CTIS β -
CTIS β - 2024-510946-15-00CTIS β
PPY988A
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2024-511381-36-00CTIS β
ASCIMINIB HYDROCHLORIDE, ASCIMINIB
Chronic Myelogenous Leukemia in chronic phase (CML-CP)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2024-511708-18-00CTIS β
JDQ443
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression β₯ 1% and an STK11 co-mutation.
-
CTIS β -
CTIS β - 2024-511934-11-00CTIS β
CLXH254C12201
Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
- 2024-512095-35-00CTIS β
CLEE011Q12101
Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2024-513086-39-00CTIS β
Zolgensma 2 Γ 10^13 vector genomes/mL solution for infusion
Spinal Muscular Atrophy
-
CTIS β -
CTIS β -
CTIS β - 2024-513281-19-00CTIS β
CDKY709A12101C
Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma
-
CTIS β -
CTIS β -
CTIS β - 2024-513613-12-00CTIS β
CLTP001A12202
Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2024-514596-18-00CTIS β
CYTB323M12101B
Difficult to treat rheumatoid arthritis, Severe, refractory Sjogrenβs disease with organ involvement
-
CTIS β - 2024-515040-23-00CTIS β
CABL001E2201
Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
-
CTIS β - 2024-515281-14-00CTIS β
CMBG453B12206B
intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
- 2024-515283-31-00CTIS β
CINC424A2X01B
This study is designed to accept patients with varied disease origins, depending on the parent protocol
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2024-518231-11-00CTIS β
CVAY736Q12202B
Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2025-521670-34-00CTIS β
CKJX839A12309
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.
- 2025-521702-18-00CTIS β
CGCJ904A12101
Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β - 2025-521912-21-00CTIS β
SODIUM CHLORIDE , DII235
Cardiovascular risk reduction in participants with elevated Lp(a)
- 2025-522019-40-00CTIS β
CABL001L12101
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
- 2025-522138-29-00CTIS β
Asciminib, ASCIMINIB HYDROCHLORIDE
Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation
-
CTIS β - 2025-523481-24-00CTIS β
CNIO752A12301
Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT01988662CT.gov β
Neovascular Age-related Macular Degeneration
Neovacular Age-related Macular Degeneration
-
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT02890069CT.gov β
PDR001
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
-
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β